CN102861084B

CN102861084B - Application of Houttuynoid D in medicine for treating ileocecum cancer

Info

Publication number: CN102861084B
Application number: CN 201210418679
Authority: CN
Inventors: 周未末; 李媛媛; 吴俊华
Original assignee: Individual
Current assignee: Nantong San Intellectual Property Service Co ltd
Priority date: 2012-10-27
Filing date: 2012-10-27
Publication date: 2013-06-19
Anticipated expiration: 2032-10-27
Also published as: CN102861084A

Abstract

The invention discloses application of Houttuynoid D in preparation of a medicine for treating ileocecum cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid D has the remarkable inhibitory effects on the growth of human ileocecum cancer cell strain HCT-8 through the evaluation of in vitro MTT antineoplastic activity. Therefore, Houttuynoid D can be used for preparing the anti-ileocecum cancer medicine and has good development and application prospects. The application of Houttuynoid D in preparation of the medicine for treating ileocecum cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid D on ileocecum cancer cells is unexpectedly strong.

Description

The application of Houttuynoid D in preparation treatment ileocecum cancer drug

Technical field

The present invention relates to the new purposes of compound H outtuynoid D, relate in particular to the application of Houttuynoid D in the anti-ileocecum cancer drug of preparation.

Technical background

Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.

the compound H outtuynoid D that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid D that the present invention relates in preparation treatment ileocecum cancer drug, because framework types belongs to brand-new framework types, and its inhibition for the ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control that is used for simultaneously the ileocecum cancer obviously has significant progress.

Summary of the invention

The invention provides the application of compound H outtuynoid D in the preparation antitumor drug.

The present invention adopts following technical scheme: the application of Houttuynoid D in the anti-ileocecum cancer drug of preparation, and the structural formula of Houttuynoid D is as shown in formula I:

The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid D also has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8, suppresses the IC of this 1 strain Growth of Cells ₅₀Value is respectively 1.83 ± 0.14 μ M.Therefore, Houttuynoid D can for the preparation of anti-ileocecum cancer drug, have good development prospect.

The purposes of the Houttuynoid D that the present invention relates in preparation treatment ileocecum cancer drug belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for the ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously the ileocecum cancer obviously has significant progress.

The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.

The specific embodiment

The preparation method of compound H outtuynoid D involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).

Embodiment 1: the preparation of compound H outtuynoid D tablet involved in the present invention:

Get 20 and digest compound Houttuynoid D, add conventional adjuvant 180 grams that prepare tablet, mixing, conventional tablet machine are made 1000.

Embodiment 2: the preparation of compound H outtuynoid D capsule involved in the present invention:

Get 20 and digest compound Houttuynoid D, add the conventional adjuvant such as starch 180 grams that prepare capsule, mixing is encapsulatedly made 1000.

Further illustrate its pharmaceutically active below by pharmacodynamic experiment.

Experimental example: adopt mtt assay assessing compound Houttuynoid D to the growth inhibited effect of human ileocecal carcinoma cell strain

1. method: the cell that is in the growth logarithmic (log) phase: human ileocecal carcinoma cell strain HCT-8(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10 ⁴The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid D of 0.0001 μ M and 0.00001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO ₂Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD _{Drug treating}/ Δ OD _Blank* 100.

2. result: Houttuynoid D has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.This compound suppresses the IC of human ileocecal carcinoma cell strain HCT-8 growth ₅₀Value is respectively: 1.83 ± 0.14 μ M.

Shown by above-described embodiment, Houttuynoid D of the present invention has good inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.Prove thus, it is active that Houttuynoid D of the present invention has anti-ileocecum cancer, can be for the preparation of anti-ileocecum cancer drug.

Claims

1.Houttuynoid the application of D in preparation treatment ileocecum cancer drug, described compound H outtuynoid D structure as Formula IShown in:

Formula I.